# US 2022/0088028 A1 · Neuronal nicotinic acetylcholine receptor partial agonists as therapeutics for chronic tinnitus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0088028 A1
- Document ID: US20220088028A1
- Status: Published application
- Kind: A1
- Application number: 17/428,164
- Filed: 2020-02-06
- Published: 2022-03-24
- Earliest claimed: 2019-02-08
- Assignees: Board of Trustees of Southern Illinois University
- Applicants: Board of Trustees of Southern Illinois University
- Inventors: Donald Caspary; Thomas Brozoski; Brandon Cox
- Web page: https://patentgrep.com/patent/US20220088028A1

## CPC

- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/4427: containing further heterocyclic ring systems
- A61P 27/16: Otologicals
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for treating a subject with symptoms of tinnitus and pharmaceutical compositions for treating tinnitus, the pharmaceutical compositions comprising one or more of the following: sazetidine, a pharmaceutically acceptable salt of sazetidine, varenicline, a pharmaceutically acceptable salt of varenicline, or any combination thereof.

## Claims

### Claim 1

A method for treating a subject in need of treatment for tinnitus, the method comprising: administering to the subject a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a therapeutically effective amount of sazetidine, varenicline, a pharmaceutically acceptable salt of sazetidine, a pharmaceutically acceptable salt of varenicline, or any combination thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition contains sazetidine and/or varenicline in the form of tartarate, lactate, citrate, succinate, bisulfate, sulfate, phosphonate, hydrochloride, monohydrogen phosphate, dihydrogen phosphate, or any combination thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered as an oral formulation, as nasal drops or a nasal spray, as ear drops or an ear spray, topically, by intravenous injection, by intramuscular injection or by subcutaneous injection.

### Claim 4 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition comprises sazetidine and/or the pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition comprises varenicline and/or the pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition comprises sazetidine hydrochloride.

### Claim 7 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition comprises varenicline tartarate.

### Claim 8 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition comprises sazetidine and/or the pharmaceutically acceptable salt thereof, and the subject is administered a dose equivalent to from about 0.1 mg to about 2 mg of sazetidine free base per day.

### Claim 9 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition comprises sazetidine and/or the pharmaceutically acceptable salt thereof and the subject is administered a dose equivalent to 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg or 0.7 mg of sazetidine free base per day.

### Claim 10 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition comprises varenicline and/or the pharmaceutically acceptable salt thereof and the subject is administered a dose equivalent to from about 0.1 mg to about 2 mg of varenicline free base per day.

### Claim 11 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition comprises varenicline and/or the pharmaceutically acceptable salt thereof and the subject is administered a dose equivalent to 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg or 0.7 mg of varenicline free base per day.

### Claim 12 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered orally.

### Claim 13 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered orally in the form of a tablet, powder, a capsule, lozenges, chewables, syrup, or aerosol.

### Claim 14 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered as nasal drops or spray or as ear drops or spray.

### Claim 15 (depends on 1)

The method of claim 1, wherein the method further comprises monitoring the subject for adverse side effects.

### Claim 16

A pharmaceutical composition for use in treating tinnitus, wherein the pharmaceutical composition comprises one or more pharmaceutically acceptable excipients and wherein the composition is characterized in that it comprises a therapeutically effective amount for treating tinnitus of an active compound wherein the active compound is one or more of the following: sazetidine, varenicline, a pharmaceutically acceptable salt of sazetidine, a pharmaceutically acceptable salt of varenicline, a sazetidine prodrug, a varenicline prodrug, a solvate of sazetidine, a solvate of varenicline, a hydrate of sazetidine, a hydrate of varenicline, or any combination thereof.

### Claim 17 (depends on 16)

The pharmaceutical composition of claim 16, wherein the pharmaceutical composition is further characterized in that it comprises sazetidine and/or the pharmaceutically acceptable salt thereof in the therapeutically effective amount equivalent to from about 0.1 mg to about 2 mg of sazetidine free base per one dose.

### Claim 18 (depends on 16)

The pharmaceutical composition of claim 16, wherein the pharmaceutical composition is further characterized in that it comprises varenicline and/or the pharmaceutically acceptable salt thereof in the effective amount equivalent to from about 0.1 mg to about 2 mg of varenicline free base per one dose.

### Claim 19 (depends on 16)

The pharmaceutical composition of claim 16, wherein the pharmaceutical composition further characterized in that it comprises varenicline tartarate and/or sazetidine hydrochloride.

### Claim 20 (depends on 16)

The pharmaceutical composition of claim 16, wherein the pharmaceutical composition is formulated as a tablet, gel capsule, powder, capsule, lozenge, chewable, syrup, a solution for oral consumption, emulsion, aerosol, nasal drops, nasal spray, ear drops, ear spray or as an injectable formulation.
